Soluble microneedle gel paste composition for resisting atherosclerosis inflammation and preparation method of soluble microneedle gel paste composition
By combining tanshinone IIA with soluble microneedles and gel ointment, the problems of poor water solubility and low bioavailability of tanshinone IIA were solved, achieving effective anti-inflammatory treatment of atherosclerotic inflammation and improving drug loading and transdermal performance.
Patent Information
- Application Number
- CN202511852621.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-10
- Publication Date
- 2026-01-16
AI Technical Summary
Tanshinone IIA has problems in clinical applications, such as poor water solubility, short half-life, and low bioavailability. In addition, the drug loading capacity of soluble microneedles in transdermal drug delivery systems is insufficient, making it difficult to effectively treat atherosclerotic inflammation.
A soluble microneedle matrix was prepared by mixing chondroitin sulfate and polyvinylpyrrolidone as needle tip matrix with tanshinone IIA. Combined with a hydrophilic gel ointment, the microneedles pierce the stratum corneum of the skin to form micropores, thereby achieving sustained-release administration of tanshinone IIA.
It improves the solubility and transdermal properties of tanshinone IIA, enabling continuous drug delivery to lesions, enhancing the anti-inflammatory effect, overcoming the limitations of insufficient drug loading, simplifying the method of use, and improving the transdermal absorption and safety of the drug.
Smart Images

Figure CN121337703A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of medical biomaterials, in particular to a soluble microneedle gel ointment composition against atherosclerotic inflammation and a preparation method thereof. BACKGROUND
[0002] Atherosclerosis is the main pathological basis of cardiovascular disease, characterized by fibrous plaques formed by lipid accumulation and inflammatory infiltration. Blood lipid management is an important means of stabilizing plaques at present, and inflammation is a residual cardiovascular risk factor under effective blood lipid management, and anti-inflammatory treatment is expected to further improve the prognosis of cardiovascular disease. Tanshinone IIA has a definite effect of anti-inflammatory and plaque stabilization, but there are difficulties in clinical application, such as difficult to dissolve in water, short half-life, low bioavailability and other application difficulties, and the rise of transdermal drug delivery system and the innovation of "needle medicine combination" instrument provide feasibility for optimizing its application. In 2022, China's heart level diagnosis and treatment expert consensus clearly pointed out that acupoint sticking, press needle and other external therapies are suitable for heart rehabilitation in stages I, II and III. The team is inspired by acupoint sticking and press needle in form and content, and extends the soluble microneedle technology with commonality, which integrates and optimizes transdermal shallow puncture and transdermal drug delivery form, and innovatively combines gel ointment to overcome the disadvantages of insufficient drug loading of soluble microneedles. SUMMARY
[0003] In order to make up for the above shortcomings, the present application provides a soluble microneedle gel ointment composition against atherosclerotic inflammation, which comprises a microneedle matrix and a gel ointment. The microneedle matrix comprises a needle tip matrix and a backing material. The microneedle matrix is formed by arranging a large number of needle tip matrices regularly on the backing material. The needle tip matrix is prepared by mixing chondroitin sulfate, polyvinylpyrrolidone and tanshinone IIA. The backing material is made of polyvinyl alcohol. The backing material is arranged at the bottom of the needle tip matrix. The gel ointment is prepared by dissolving, stirring and baking hydrophilic gel special polyacrylic acid sodium NP-700, glycerol, glycol aluminum hydroxide, tartaric acid, ethylenediaminetetraacetic acid disodium EDTA-2Na, polyvinyl alcohol PVA and tanshinone IIA. The gel ointment is arranged at the bottom of the microneedle matrix.
[0004] The mass ratio of chondroitin sulfate and polyvinylpyrrolidone of the needle tip matrix is 1:1, and 0.8g-1.2g is selected, the concentration options of tanshinone IIA of the needle tip matrix can be 3mg / ml, 9mg / ml, 12mg / ml, 15mg / ml, 18mg / ml and 21mg / ml, the percentage of the specific components of the gel paste is NP-700: 5.0%, glycerol: 40%, glycyrrhizic acid: 0.3%, tartaric acid: 0.2%, disodium EDTA-2Na: 0.05%, polyvinyl alcohol PVA: 0.5%, and the input amount of tanshinone IIA in the gel paste can be 1mg, 3mg, 5mg and 7mg respectively.
[0005] The content of tanshinone IIA in the soluble microneedle gel paste composition is 841.31±7.34µg.
[0006] The back surface of the backing material has a circle of side walls perpendicular to the back surface of the backing material, and the side walls and the back surface of the backing material form a concave surface, and the gel paste is filled in the concave surface.
[0007] The back surface of the backing material is provided with a small concave surface at the position corresponding to the needle tip matrix, and the gel paste also fills the small concave surface.
[0008] Meanwhile, the application also provides a preparation method of the soluble microneedle gel paste composition for resisting atherosclerotic inflammation, characterized by comprising the following steps: Step 1, preparing a needle tip matrix, selecting chondroitin sulfate CS and polyvinylpyrrolidone PVP-K30 as the needle tip matrix material, taking a certain amount of chondroitin sulfate and polyvinylpyrrolidone and adding 1 times of ethanol aqueous solution (w / w) to stir uniformly, adding different gradient doses of tanshinone IIA, and placing in a 4 ℃ refrigerator overnight until swelling completely, pouring the micro-needle mold groove surface, centrifuging at 4000 r / min for 10 minutes to make the solution fully fill in the micropores, scraping off the excess matrix solution outside the needle tip with a medicine spoon, and drying in a desiccator at room temperature for 30 minutes to obtain the needle tip matrix / needle tip drug loading layer; Step 2, preparing a 15% polyvinyl alcohol PVA backing matrix solution with ethanol aqueous solution as the solvent overnight to make it completely swell; Step 3, preparing a soluble microneedle, adding the 15% polyvinyl alcohol PVA backing matrix solution in step 2 to the micro-needle mold in step 1 for secondary centrifugation treatment to remove air bubbles in the matrix solution under the same conditions, and drying in a desiccator at room temperature for 24 hours to obtain a soluble microneedle matrix; Step 4, first add the hydrophilic gel special polyacrylic acid sodium NP-700 into the beaker containing glycerol, and mix well at a speed of 200 rpm as phase A; take tartaric acid and ethylenediaminetetraacetic acid disodium EDTA-2Na as phase B, add different gradient doses of tanshinone IIA into phase B, mix with appropriate amount of ethanol aqueous solution; add polyvinyl alcohol PVA into the ethanol aqueous solution, and place overnight to swell sufficiently to remove the generated bubbles as phase C; add alumin(i)um glycinate into appropriate amount of glycerol, and stir well until completely dissolved to obtain phase D; Step 5, add phases B and C into phase A respectively under stirring at a speed of 200 rpm, then add phase D and stir to form a semi-viscous solid fluid, after ultrasonic treatment for 30 minutes, coat it on the non-woven fabric, and place it in an oven at 50℃ for 24 hours to prepare the gel paste; Step 6, fill appropriate amount of gel paste into the back of the soluble microneedle matrix obtained in step 3.
[0009] For step 3, there are two optional preferred modes as follows: The last soluble microneedle matrix in step 3 is still in the microneedle mold, and in step 6, appropriate amount of gel paste is filled into the microneedle mold, and the gel paste fills the concave surface on the back of the soluble microneedle matrix.
[0010] The last soluble microneedle matrix in step 3 is demolded, and in step 6, appropriate amount of gel paste is filled into the concave surface on the back of the soluble microneedle matrix.
[0011] For step 1, the preferred mode is as follows: In step 1, chondroitin sulfate and polyvinylpyrrolidone are taken as 1 g respectively, and 2 ml of ethanol aqueous solution (w / w) is added and stirred uniformly, the concentration of the ethanol aqueous solution is 50%-70%, and the different gradient doses of tanshinone IIA are specifically 3 mg / ml, 9 mg / ml, 12 mg / ml, 15 mg / ml, 18 mg / ml and 21 mg / ml concentration options, then 2 ml of ethanol aqueous solution is used, and the amount of 6 mg, 24 mg, 30 mg, 36 mg and 42 mg is used.
[0012] For step 4, the preferred mode is as follows: In step 4, the different gradient doses of tanshinone IIA can be specifically selected as 1 mg, 3 mg, 5 mg and 7 mg.
[0013] The beneficial effects of the present application: the present application combines the preparation process parameters of tanshinone II A-soluble microneedle (TSA-DMN) and tanshinone II A (TSA)-gel ointment, and combines the two to prepare a TSA-DMN-gel ointment composite drug delivery system. After the needle tip array of the system pierces the stratum corneum of the skin and leaves a micropore channel, a small dose of TSA in DMN and a large dose of TSA in the gel ointment are released into the channel, realizing continuous drug delivery to the lesion, thereby solving the low drug loading of TSA-DMN, breaking through the limitations of the poor transdermal performance of TSA gel ointment, and significantly enhancing the anti-inflammatory effect. The present application provides a new idea and method for further improving the drug loading of traditional Chinese medicine microneedle preparation and enhancing the transdermal absorption of the preparation mode. BRIEF DESCRIPTION OF DRAWINGS
[0014] Figure 1 It is a side cross-sectional view of the composition of the present application.
[0015] Figure 2 It is a top view of the microneedle tool used in the present application.
[0016] Figure 3 It is a side cross-sectional view of the microneedle tool used in the present application.
[0017] Figure 4 It is an appearance form diagram of the soluble microneedle.
[0018] Figure 5 It is a mechanical strength observation diagram of the soluble microneedle.
[0019] Figure 6 It is a TSA specificity HPLC diagram.
[0020] Figure 7 It is a TSA standard curve diagram.
[0021] Figure 8 It is a gel ointment appearance observation diagram.
[0022] Figure 9 It is a comparison diagram of the present application and a simple microneedle group.
[0023] Figure 10 It is a physical diagram of the soluble microneedle gel ointment combination of the present application.
[0024] Figure 11 It is a physical diagram of the present application when the backing material is upside down. DETAILED DESCRIPTION
[0025] The English abbreviations appearing throughout the specification are explained as follows: tanshinone IIA-TSA, dissolving microneedle-DMN, tanshinone IIA dissolving microneedle-TSA-DMN, sodium polyacrylate for hydrophilic gel-NP-700, disodium ethylenediaminetetraacetate-EDTA-2Na, polyvinyl alcohol-PVA, chondroitin sulfate-CS, polyvinylpyrrolidone-PVP-K30.
[0026] To make up for the deficiencies introduced in the background art, as shown in Figure 1 The present application is a dissolving microneedle gel composition for combating atherosclerotic inflammation, which comprises a microneedle matrix and a gel 1, the microneedle matrix comprises a needle tip matrix 2 and a backing material 3, the microneedle matrix is formed by a large number of needle tip matrices 2 regularly arranged on the backing material 3, the needle tip matrix 2 is prepared by mixing chondroitin sulfate and polyvinylpyrrolidone with tanshinone IIA, the backing material 3 is made of polyvinyl alcohol, the backing material 3 is arranged at the bottom of the needle tip matrix 2, and the gel 1 is prepared by dissolving, stirring and baking sodium polyacrylate for hydrophilic gel NP-700, glycerol, glycol aluminum hydroxide, tartaric acid, disodium ethylenediaminetetraacetate EDTA-2Na, polyvinyl alcohol PVA and tanshinone IIA, and the gel 1 is arranged at the bottom of the microneedle matrix.
[0027] The preferred structure is as follows: 1) The mass ratio of chondroitin sulfate to polyvinylpyrrolidone in the needle tip matrix is 1:1, and the amount is selected from 0.8g to 1.2g, the concentration of tanshinone IIA in the needle tip matrix can be selected from 3mg / ml, 9mg / ml, 12mg / ml, 15mg / ml, 18mg / ml and 21mg / ml, and the percentage of the specific components of the gel is as follows: NP-700: 5.0%, glycerol: 40%, glycol aluminum hydroxide: 0.3%, tartaric acid: 0.2%, disodium ethylenediaminetetraacetate EDTA-2Na: 0.05%, polyvinyl alcohol PVA: 0.5%, and the amount of tanshinone IIA in the gel can be selected from 1mg, 3mg, 5mg and 7mg.
[0028] The content of tanshinone IIA in the dissolving microneedle gel composition is 841.31±7.34µg.
[0029] 2) The back surface of the backing material 3 has a circle of side walls 4 perpendicular to the backing material, the height of the side walls 4 is 2.5mm, the side walls 4 and the back surface of the backing material 3 form a concave surface 5, and the gel 1 is filled in the concave surface 5, as shown in Figure 1 .
[0030] 3) The back of the backing material 3 is provided with a small concave surface 6 at the position corresponding to the tip of the matrix 2, and the gel paste 1 also fills the small concave surface 6, as shown in Figure 10
[0031] The TSA-DMN is observed by naked eye and optical microscope to evaluate the integrity of the microneedle array and the flatness of the backing, and to observe the distribution and appearance of the needle body, as shown in Figure 3 The prepared TSA-DMN array is intact and uniform in orange red color under visual observation; the microneedles are orderly arranged, uniformly distributed, and in good condition without broken needles under microscopic observation.
[0032] For the above introduction of the basic content of the structure selected, tanshinone IIA (TanshinoneIIA, TSA) is an active component in the blood-activating and stasis-removing drug Danshen, which has good anti-inflammatory, anti-infection, and immune regulation effects. The molecular formula of TSA is C 19 H 18 O3, and the relative molecular mass is 294.33, and the structural formula is as shown in FIG. 1. TSA is a cherry red needle-shaped crystal with fat solubility, which is slightly soluble in water, and easily soluble in organic solvents such as diethyl ether, acetone, ethanol, benzene, etc., but the stability of its ethanol solution and aqueous solution gradually decreases with the increase of temperature. Due to its quinone structure, the electronic behavior of TSA shows high activity, and is easy to undergo oxidation-reduction reaction, thereby participating in various biochemical reactions in the body and exhibiting multiple biological activities. TSA has fat solubility, and is easy to decompose under light and heat, and has poor transdermal absorption, which restricts its drug efficacy. Therefore, the present application combines TSA with microneedles to improve the solubility and transdermal performance of TSA. The microneedle technology refers to a micro needle processed by micro casting or micro electronic manufacturing technology using metal, ceramic, silicon and other materials. The microneedle array has the ability to quickly penetrate the skin and penetrate the stratum corneum. Through this physical puncture effect, the drug can reach the designated depth of the skin with the microneedle, thereby playing a pharmacological role in the subcutaneous tissue or entering the blood circulation. The transdermal drug delivery system has multiple advantages such as improving the transdermal performance of the drug, enhancing the patient's adaptability, being convenient to operate, being non-invasive, having almost no pain, and having safe and controllable dose.
[0033] According to the difference of its internal structure, microneedles can be classified into two categories: hollow microneedles and solid microneedles. Solid microneedles can be classified into three types: coated microneedles, dissolvable microneedles and hydrogel microneedles under different drug loading methods. Dissolving microneedle (DMN) is one of the main types of microneedles. It is prepared by mixing drugs and degradable polymer materials, using solvent dissolution and melting method to inject the polymer material containing drugs into the microneedle mold, and then through a series of operations such as cooling and drying. Because it has many advantages, it has become a research hotspot in transdermal drug delivery system in recent years.
[0034] Meanwhile, the application also provides a preparation method of the dissolvable microneedle gel composition for resisting atherosclerotic inflammation, characterized by comprising the following steps: Step 1, preparing a needle tip matrix, selecting chondroitin sulfate CS and polyvinylpyrrolidone PVP-K30 as the needle tip matrix material, taking a certain amount of chondroitin sulfate and polyvinylpyrrolidone and adding 1 times of ethanol aqueous solution (w / w) to stir uniformly, and adding different gradient doses of tanshinone IIA and placing in a 4 ℃ refrigerator overnight until swelling completely, pouring the microneedle mold groove surface, see Figure 2 and Figure 3 Centrifuging at 4000 r / min for 10 minutes to make the solution fully fill the micropores, scraping off the excess matrix solution outside the needle tip with a medicine spoon, and drying in a desiccator at room temperature for 30 minutes to obtain the needle tip matrix / needle tip drug loading layer; Step 2, preparing a 15% polyvinyl alcohol PVA backing matrix solution with ethanol aqueous solution as the solvent overnight to make it completely swell; Step 3, preparing the dissolvable microneedle, adding the 15% polyvinyl alcohol PVA backing matrix solution in step 2 to the microneedle mold in step 1 for secondary centrifugal treatment to remove air bubbles in the matrix solution under the same conditions, and drying in a desiccator at room temperature for 24 hours to obtain the dissolvable microneedle matrix; Step 4, first adding hydrophilic gel special sodium polyacrylate NP-700 into a beaker containing glycerol and mixing uniformly at a speed of 200 rpm as phase A; taking tartaric acid and disodium EDTA-2Na as phase B, adding different gradient doses of tanshinone IIA into phase B and mixing uniformly with a proper amount of ethanol aqueous solution; adding polyvinyl alcohol PVA into ethanol aqueous solution, placing overnight to swell completely to remove air bubbles as phase C; adding aluminum glycyrrhizinate into a proper amount of glycerol and stirring fully until completely dissolved to obtain phase D; Step 5, adding phases B and C into phase A respectively under the stirring speed of 200 rpm, then adding phase D to stir uniformly into a semi-viscous solid fluid, coating the fluid on non-woven fabric after ultrasonic treatment for 30 minutes, and placing in an oven for drying at 50 ℃ for 24 hours to prepare the gel paste; Step 6, fill the back of the last soluble microneedle matrix of step 3 with an appropriate amount of gel paste.
[0035] There are two alternative preferred ways for step 3 as follows: The last soluble microneedle matrix of step 3 is still in the microneedle mold, and in step 6, an appropriate amount of gel paste is filled into the microneedle mold, and the gel paste fills the concave surface on the back of the soluble microneedle matrix.
[0036] The last soluble microneedle matrix of step 3 is demolded, and in step 6, an appropriate amount of gel paste is filled into the concave surface on the back of the soluble microneedle matrix.
[0037] The preferred way for step 1 is as follows: In step 1, 1 g of chondroitin sulfate and 1 g of polyvinylpyrrolidone are taken and stirred uniformly with 2 ml of an ethanol aqueous solution (w / w), and the ethanol aqueous solution has a concentration of 50%-70%. The different gradient doses of tanshinone IIA can be specifically selected from the concentration options of 3 mg / ml, 9 mg / ml, 12 mg / ml, 15 mg / ml, 18 mg / ml, and 21 mg / ml, and then 2 ml of the ethanol aqueous solution is used, and the amount of 6 mg, 24 mg, 30 mg, 36 mg, and 42 mg is used.
[0038] The preferred way for step 4 is as follows: In step 4, the different gradient doses of tanshinone IIA can be specifically selected from 1 mg, 3 mg, 5 mg, and 7 mg.
[0039] The TSA is prepared into a soluble microneedle, which can fully exert the excellent drug release performance of the soluble microneedle, break through the limitations of external application of drugs, and realize intralesional drug use; can be evenly distributed in the body, which is beneficial to the exertion of therapeutic effect and the avoidance of adverse reactions caused by local tissue damage. The use method of the drug is simplified, the operation is convenient, and after taking the drug, any auxiliary means is not needed to promote the transdermal and absorption of the drug, which increases the compliance of the patient in taking the drug. In the preparation, one or several transdermal enhancers and surfactants do not need to be added, which reduces the skin irritation of the preparation and the cost of the preparation to some extent, and reduces the psychological and economic burden of the patient; at the same time, targeted release can also be realized to improve the therapeutic effect of the drug. Compared with metal microneedles and silicon microneedles, the DMN uses a high polymer biological material as a preparation substrate, there is no risk of needle breakage after piercing the skin, the safety of drug use is improved, the gel paste is filled in the groove on the back of the microneedle in the form of a patch, which increases the adhesion and improves the drug loading capacity, thereby providing a new idea for the innovation of traditional Chinese medicine transdermal preparations. Figure 2 and Figure 3
[0040] The preparation process is divided into three parts, the first part is the preparation of tanshinone IIA soluble microneedle, the second part is the preparation of tanshinone IIA gel paste, and the third part is the combination of soluble microneedle and gel paste, and the above three parts are given as follows according to the actual experimental process: Experimental example 1-1: The preparation instrument and reagent of tanshinone IIA soluble microneedle: The instrument is selected from the following specific manufacturers and models:
[0041] The reagent is selected from the following specific manufacturers and models:
[0042] Step 1, preparation of needle tip matrix, chondroitin sulfate CS and polyvinylpyrrolidone PVP-K30 are selected as needle tip matrix materials, 1g of chondroitin sulfate and polyvinylpyrrolidone are taken and 1 times amount of 50% concentration ethanol aqueous solution (w / w) is added, i.e. 2ml, and 30mg of tanshinone IIA is added, which is placed in a 4℃ refrigerator overnight until it is completely swollen, the solution is poured into the groove surface of the microneedle mold, centrifuged at 4000r / min for 10 minutes, the solution is fully filled in the micropores, the excess matrix solution outside the needle tip is scraped off with a medicine spoon, and the needle tip matrix / needle tip drug-loaded layer is obtained after drying in a desiccator at room temperature for 30 minutes; Step 2, prepare 15% polyvinyl alcohol PVA backing matrix solution with ethanol aqueous solution as solvent overnight to make it completely swollen; Step 3, preparation of soluble microneedle, add the 15% polyvinyl alcohol PVA backing matrix solution in step 2 to the microneedle mold in step 1 for secondary centrifugal treatment, remove the air bubbles in the matrix solution under the same conditions, and obtain the soluble microneedle matrix TSA-DMN after drying in a desiccator at room temperature for 24 hours.
[0043] Single factor test is conducted on experimental example 1: In order to ensure that the prepared matrix solution (or drug-containing matrix solution) has good fluidity, so as to be used for pouring in the microneedle mold, it is necessary to use drugs and materials with good solubility at the same time, and the appearance form and puncture rate of the microneedle are also important indicators for evaluating the hardness and mechanical properties. Therefore, in this study, the solubility of the drug, the fluidity, formability and skin puncture rate of the matrix solution are used as evaluation indexes, and the single factor method is used to optimize the process parameters of the needle tip drug-loaded needle tip layer. The ratio of the number of needle holes penetrating the skin to the number of microneedle arrays is an index for measuring the skin puncture rate. The evaluation standard is shown in the following table (soluble microneedle needle tip process layer evaluation standard).
[0044] To make the drug and solvent have better solubility, the experiment uses ethanol solution as the solvent to dissolve the drug. With the method for evaluating the process layer of the tip of the soluble microneedle as the evaluation index, the dissolution of the drug is investigated when the content of ethanol in the solvent is 20%, 30%, 40%, 50%, 60% and 70% respectively, the optimal volume fraction of the ethanol aqueous solution is screened, and the screening structure in the following table is obtained.
[0045] The solvent screening result is shown in the above table, and the TSA is completely dissolved in the range of 50%-70% of the content of ethanol. Since ethanol has irritancy to the skin, the lower the content of ethanol is, the better, and in order to ensure the drug solubility and the performance of the microneedle, 50% of the ethanol aqueous solution is finally selected as the solvent for dissolving the drug.
[0046] According to the different drug loading capacity of the tip, the tip drug loading capacity is optimized by evaluating the flowability of the microneedle matrix solution, the microneedle forming property and the skin puncture rate index when the drug concentration is 3 mg / mL, 9 mg / mL, 12 mg / mL, 15 mg / mL, 18 mg / mL and 21 mg / mL respectively, and the screening result of the tip drug loading capacity in the following table is obtained.
[0047] The drug concentration screening result is shown in the above table, and the different drug loading concentration has a great influence on the mechanical strength of the microneedle. Appropriately increasing the drug loading capacity can effectively improve the mechanical strength of the microneedle, and when the drug loading capacity increases to a certain extent, the mechanical strength decreases. The result shows that when the tip drug loading capacity of the microneedle is 15 mg / mL, the mechanical strength of the microneedle decreases. When the drug loading capacity is 3 mg / mL, 9 mg / mL, 12 mg / mL and 15 mg / mL, the score value is the highest, therefore, the tip drug loading capacity of 15 mg / mL is the best.
[0048] The preparation of the experimental example 1 is combined with the soluble microneedle structure of the application, and the morphological characteristics are verified as follows: The healthy SD rats are sacrificed by cervical dislocation, fixed on the operation table for depilation, and then the skin is peeled off, and the subcutaneous fat is cleaned with degreasing cotton to obtain the isolated skin of the rat. Before use, the skin is activated by soaking in normal saline for 30 min, wiped dry with filter paper, placed with the horny layer side upward, and the TSA-DMN is vertically applied to the skin surface for 30 s, dyed with an appropriate amount of trypan blue solution, and the dyeing pore condition on the skin surface is observed.
[0049] Puncture performance of TSA-DMN on the skin of joint muscle part of rats. The TSA-DMN was vertically punctured on the smooth and hairless joint muscle of rats (hair removal was performed 24 h before the test using an animal hair removal machine and hair removal cream), and removed after 30 s of action. Photographs were taken using a mobile phone to observe the puncture of the microneedle into the skin of the rats. Whether the hardness meets the standard and whether the puncture performance is good, the skin puncture results are shown in Figure 4 The TSA-DMN can successfully puncture the isolated skin of rats and the joint muscle part in vivo, indicating that the prepared soluble microneedle has good mechanical strength and puncture ability.
[0050] Methodological investigation and drug content determination of TSA-DMN with tanshinone IIA: 1) Chromatographic conditions of HPLC content determination method: Reference [8] The chromatographic conditions are Agilent C18 (250 mm x 4.6 mm, 5 μm) chromatographic column; mobile phase is methanol-water (75:25); volume flow rate is 1 mL / min; column temperature is 30 °C; detection wavelength is 270 nm; injection volume is 10 μL.
[0051] 2) Preparation of reference solution: precisely weigh 2.5 mg of TSA reference substance, place it in a 25 mL volumetric flask, dissolve and dilute with methanol to obtain a 100 μg / mL reference solution. From the reference solution, precisely measure 5 mL and dilute to 25 mL in a 25 mL volumetric flask to obtain a 20 μg / mL reference solution.
[0052] 3) Preparation of test solution: Place 1 piece of self-made TSA-DMN in a 25 mL volumetric flask, add methanol to dilute, and ultrasonic for 1 h. After complete dissolution, it is used as the test solution.
[0053] 4) Preparation of blank microneedle solution: Place 1 piece of self-made blank DMN in a 25 mL volumetric flask, add methanol to dilute, and ultrasonic for 1 h to obtain the blank microneedle solution.
[0054] 5) Specificity investigation: According to the chromatographic conditions in 1, the three solutions prepared in 2 (TSA reference solution, test solution and blank microneedle solution) were determined, and the specificity investigation results are shown in Figure 5 As shown in the figure, the blank microneedle solution does not have a peak at the peak of the target component, and the separation effect of the target component is good, indicating that the method has good specificity.
[0055] 6) Investigation of linear relationship The precision TSA control solution was diluted with methanol to prepare control solutions with mass concentrations of 2 µg / mL, 4 µg / mL, 10 µg / mL, 20 µg / mL, 50 µg / mL, and 100 µg / mL of TSA, respectively. Linear regression determination was performed, and the linear relationship is shown in Figure 6 The regression equation is Y = 60668X + 58460 (R 2 = 0.9997), indicating that TSA has a good linear relationship in the range of 2.00-100.00 µg / mL.
[0056] 7) Precision test The 20 µg / mL TSA control solution was repeatedly injected for detection 5 times, and the relative standard deviation RSD was calculated. The precision test results are shown in the following table. The RSD value of the 20 µg / mL TSA precision is less than 2%, indicating that the HPLC has good accuracy and can realize continuous determination of the sample.
[0057] 8) Stability test The test sample solution was injected for analysis at 0, 2, 4, 8, 12, and 24 h, respectively, and the relative standard deviation RSD was calculated. The stability test results are shown in the following table. The RSD value of the TSA stability is less than 2%, indicating that TSA meets the stability test requirements during the 24-hour detection process.
[0058] 9) Reproducibility test
[0059] Five TSA-DMNs from the same batch were prepared according to the method described in "3.3.3", and the chromatographic method in "3.3.1" was used for continuous injection. The relative standard deviation RSD of the sample was calculated, and the reproducibility test results are shown in the following table. The RSD value is less than 2%, indicating that the method has good reproducibility.
[0060] 10) Sample addition recovery rate test Six blank microneedles were taken and placed in 25 mL volumetric flasks. Solutions containing TSA control substances with mass concentrations of 40.235, 50.294, and 60.353 µg / mL were added, respectively. After complete dissolution, the sample was injected for analysis, and the average sample addition recovery rate and RSD were calculated. The sample addition recovery rate test results are shown in the following table. The average sample addition recovery rate of TSA is 95.13-100.12%, and the RSD value is less than 2%, indicating that it meets the experimental requirements.
[0061] 11) Drug content determination of TSA-DMN Take 3 portions of the same batch of TSA-DMN, prepare the solution according to the test sample preparation method in item “3.3.3”, analyze by injecting according to the chromatographic conditions in item “3.3.1”, calculate the drug loading of each TSA-DMN, and the MN drug content determination results are shown in the following table. The average drug loading of each microneedle is (57.64 ± 1.28) μg.
[0062] The experimental example 1-1 of the present application first optimizes the screening of the dissolving drug solvent and the drug mass concentration of the needle tip for preparing microneedles, single factor optimizes the process parameters of the needle tip layer, and optimizes the preparation process of TSA-DMN. It is determined that 50% ethanol solution is the drug solvent, and the total mass concentration of the drug in the needle tip is 15 mg / mL. According to the optimized process, 3 batches of TSA soluble microneedle samples are prepared, which have good appearance and mechanical properties. The skin puncture results show that TSA-DMN soluble microneedles can successfully puncture the isolated skin of rats and the skin at the joint muscle in vivo, and the mechanical strength of the prepared soluble microneedles is good, and the puncture ability is excellent. The drug content of each piece is (57.64 ± 1.28) μg.
[0063] Experimental example 1-2: Preparation of tanshinone IIA gel paste: The following instruments are selected:
[0064] The following reagents are selected:
[0065] The prescription of TSA gel paste base is: NP700: 5.0%, glycerol: 40%, glycyrrhizinate: 0.3%, tartaric acid: 0.2%, EDTA-2Na: 0.05%, PVA: 0.5%.
[0066] Phase A: NP700 5.0%, glycerol 30%; Phase B: tartaric acid 0.2%, EDTA-2Na 0.05% Phase C: PVA 0.5%; Phase D: glycyrrhizinate 0.2%, glycerol 10%; The remaining substances are 50% ethanol aqueous solution.
[0067] NP-700 was first added to a beaker containing glycerol and mixed at a speed of 200 rpm as phase A; 3 mg of TSA was added to phase B (tartaric acid, EDTA-2Na) and mixed with an appropriate amount of ethanol water solution; PVA was added to the ethanol water solution and left overnight to swell completely to remove the generated bubbles as phase C; and aluminium glycerophosphate was added to an appropriate amount of glycerol and stirred thoroughly until completely dissolved to obtain phase D.
[0068] Phases B and C were added to phase A at a stirring speed of 200 rpm, and phase D was then added and stirred to form a semi-viscous solid fluid. After ultrasonic treatment for 30 min, the semi-viscous solid fluid was coated on a non-woven fabric and placed in an oven at 50°C for 24 h to prepare a TSA gel ointment.
[0069] An evaluation method was established for the preparation method of Experimental Example 1-2. The quality evaluation of the gel ointment includes two aspects, one is the physicochemical properties of the gel ointment itself, such as appearance, qualitative and quantitative determination of active ingredients, etc.; and the other is the adhesion of the gel ointment, which can more directly reflect the quality of the gel ointment and has the greatest impact on the quality of the gel ointment. Therefore, it is very important to comprehensively and systematically investigate the comprehensive performance of the gel ointment itself and its matrix material. In the process of studying the matrix of the gel ointment, the comprehensive sensory index was mainly used to evaluate the performance of the gel ointment. The comprehensive sensory evaluation index was based on the appearance of the ointment, the comfort of being attached to the skin, the skin following property, the residual property and the repeated peeling property, and was evaluated by scoring method, with a full score of 5 points for each index and a total score of 25 points. The specific requirements of the comprehensive sensory evaluation score are shown in the following table.
[0070] Optimal selection of the dosage of the gel ointment formula of the present application: Verification of the dosage of the tackifier PVA: PVA was used as the tackifier in the formula, and the dosage thereof was 0.1%-1.5% through pre-experiment. As can be seen from the following table, when the dosage of PVA was in the range of 0.5%-1%, the initial tackiness and tackiness retention of the matrix were both good, but as the dosage of PVA increased, the matrix became soft and the tackiness decreased slightly. Therefore, the dosage of PVA was determined to be 0.5%.
[0071] Verification of the dosage of the crosslinking agent aluminium glycerophosphate: When the content of the crosslinking agent aluminium glycerophosphate was too high, the gel matrix was crosslinked too much, white flocculent substances were produced, and the matrix was hard; when the content of the crosslinking agent aluminium glycerophosphate was too low, the whole gel ointment was not formed and the adhesion was poor. The properties of the gel ointment matrix were investigated when the dosage of the crosslinking agent aluminium glycerophosphate was 0.1%-0.3%, and the results are shown in the following table.
[0072] From the above table, the gel matrix of 0.2% ganxiny aluminum presents moderate viscosity and good excipient, and there is no matrix hardening, and the sensory comprehensive score is the best. Therefore, the content of ganxiny aluminum is determined as 0.2%.
[0073] Verification of the drug loading capacity of the matrix: the drug was dissolved in 50% ethanol solution as solvent, mixed uniformly with PVA, and other components were prepared according to the blank matrix formula selected, to prepare Danshentong II A gel ointment. The unit drug loading capacity of 1.0 mg, 3.0 mg, 5.0 mg, and 7.0 mg was selected for single factor investigation. The results are shown in the following table.
[0074] From the above table, when the drug dosage is small, the performance of the ointment changes little; with the increase of drug content, the performance of the matrix decreases, and the gel ointment containing 3.0 mg of Danshentong II A has the highest sensory comprehensive score. Therefore, the amount of Danshentong II A is determined as 3.0 mg.
[0075] Verification of the properties of the drug-containing gel ointment: According to the 2020 edition of Chinese Pharmacopoeia, the appearance of the self-made TSA gel ointment is uniform orange-red gel ointment, as shown in Figure 7 .
[0076] 5) Verification of the determination of the content of Danshentong II A in gel ointment by HPLC method: A) Preparation of test solution: Take the gel ointment that can fill and coat the micro-needle groove into a 25 ml capacity bottle, add methanol to constant volume, ultrasonic treatment for 1 h, and filter after one day to obtain.
[0077] B) Sample content determination: Prepare test solution from three batches of drug-loaded gel ointment respectively, analyze the sample under the same chromatographic conditions of micro-needle, determine the peak area of TSA, calculate the drug loading capacity, and the results of gel ointment drug content determination are shown in the following table. The average drug loading of each gel ointment is (876.64 ± 8.41) µg.
[0078] In this experimental example 1-2, the amount of glycerol aluminum glycyrrhizinate and polyvinyl alcohol (PVA) and the drug loading capacity of the gel base were investigated by single factor experiment, with the comprehensive sensory evaluation (uniformity, spreadability, film residue, exudation, skin followability) as the evaluation index to screen the preparation process; the appearance and the content of tanshinone II A determined by HPLC were evaluated. The optimized gel base formulation was glycerol: sodium polyacrylate-700: glycyrrhizinate aluminum: PVA: tartaric acid: EDTA-2Na ratio of 40%:5.0%:0.2%:0.5%:0.2%:0.05%, the drug loading capacity of the base was 3 mg, the appearance of the base prepared by the optimized formulation was uniform, soft and moderate, with good skin followability and good adhesion; the content of each tablet determined by HPLC was (876.64±8.41) µg.
[0079] Experimental example 1-3: Combination of soluble microneedles and gel paste: The instruments used are as follows:
[0080] The reagents used are as follows:
[0081] 1) Evaluation index of combination method: The evaluation index is whether the gel paste can fill the microneedle groove, the appearance of the microneedle, and whether the mechanical strength of the needle tip is affected.
[0082] 2) Combination method of TSA-DMN-gel paste drug loading system: Method 1: Put the prepared paste into an oven at 50℃ for 24h, then take an appropriate amount to fully fill the microneedle (which has been demolded) backing space.
[0083] Method 2: Place a release paper on the surface of the microneedle mold groove to fully contact (the purpose is to avoid the residual of the formed gel paste in the microneedle mold, which is convenient for taking out), pour the prepared paste with good fluidity into the microneedle mold groove, centrifuge at 4000 r / min for 10 min to completely fill it, and then put it into an oven at 50℃ for 24h.
[0084] Method 3: Fill the gel paste with certain fluidity into the microneedle backing which has not been demolded but has been dried, and then dry it in a normal temperature dryer.
[0085] The structure of method 1 and method 3 can fill the microneedle groove; the appearance shape is good, and the mechanical strength of the needle tip is good, but method 3 is more stable, and method 1 is prone to accidental situations in the process, that is, it has no stable reliability, and method 2 has the same performance but cannot fill the microneedle groove, as shown in Figure 9 .
[0086] 3) Drug loading determination of TSA gel paste dissolvable microneedles Take 3 TSA gel paste dissolvable microneedles prepared from the same batch, respectively, and place them in 25 mL volumetric flasks. Add methanol and ultrasonicate for 1 h, then dilute to volume. Filter through a 0.45 µm microporous filter membrane. Inject 10 µL of the sample under the same chromatographic conditions as the microneedles. Calculate the drug loading of each microneedle. The drug loading determination results of the TSA gel paste dissolvable microneedles are shown in the following table. The average drug loading of each combined microneedle is (841.31 ± 7.34) µg.
[0087] Experimental Example 1-4: Effect of TSA-DMN-gel paste drug delivery system on improving the inflammatory state of atherosclerotic mice: The instruments used are as follows:
[0088] The reagents used are as follows:
[0089] The experimental animals used are as follows: SPF grade C57BL / 6J mice and C57BL / 6J background ApoE- / - mice, 8 weeks old, weighing (22 ± 2) g, provided by Beijing Sibeifeng Biotechnology Co., Ltd. (License No.: SCXK (Jing) 2019-0010), housed in cages of 6 per cage in the Experimental Animal Institute of Guizhou University of Chinese Medicine, with free access to water and ordinary feed. The temperature was maintained at 22 ± 2°C, and the indoor lighting was artificially controlled to maintain a 12 h light cycle (08:00-20:00) and a 12 h dark cycle (20:00-08:00) alternately.
[0090] Step 1: After 1 week of adaptation to ordinary feed, 6 C57BL / 6J mice were fed with ordinary feed, and 24 C57BL / 6J background ApoE - / - The mice were fed with high-fat feed (formulation: 38.4% carbohydrates, 22.5% fat, 21.3% protein, 5.7% crude fiber, 1.8% calcium, and 1.2% phosphorus) for 8 weeks to prepare an atherosclerotic model.
[0091] Step 2: 6 C57BL / 6J mice were set as the blank group, and 24 C57BL / 6J background ApoE - / - The mice were randomly divided into model group, simple microneedle group, simple gel paste group, and gel paste microneedle combination group, with 6 mice in each group.
[0092] Step 3, Blank group: Normal feed, catch, fixed 20 min, 1 time a day, 8 weeks.
[0093] Model group: Normal feed, catch, fixed 20 min, 1 time a day, 8 weeks.
[0094] Simple microneedle group: Normal feed, catch, fixed 20 min, 1 time a day, 8 weeks. In addition, each mouse was treated with chest hair removal and routine disinfection, and was given TSA-DMN and appropriate pressure, 1 piece each time, 1 time every other day, for 8 weeks.
[0095] Simple gel paste group: Normal feed, catch, fixed 20 min, 1 time a day, 8 weeks. In addition, each mouse was treated with chest hair removal and routine disinfection, and was given TSA-gel paste and appropriate pressure, 1 piece each time, 1 time every other day, for 8 weeks.
[0096] Gel paste microneedle combination group: Normal feed, catch, fixed 20 min, 1 time a day, 8 weeks. In addition, each mouse was treated with chest hair removal and routine disinfection, and was given TSA-DMN-gel paste and appropriate pressure, 1 piece each time, 1 time every other day, for 8 weeks.
[0097] Step 4, after the last intervention, the mice were fasted for 12 hours without water, and blood collection was completed. Blood was collected from the orbital venous plexus of the mice by enucleation, about 1-1.5 mL, placed in a 2 mL EP tube, and after standing at room temperature for 1 hour, placed in a 4°C low temperature centrifuge at a speed of 3000 rpm for 10 minutes. After centrifugation, the serum was stored in a -80°C refrigerator for use in inflammatory factor detection.
[0098] Step 5, detect the content of serum interleukin-6 (Interleukin-6, IL-6), IL-8 (Interleukin-8, IL-8), tumor necrosis factor-α (tumor necrosis factor, TNF-α) in each group of mice. The serum sample was pretreated by centrifugation at 3000 rpm for 10 min, and the supernatant was detected by ELISA method, the method was as follows: (1) Reagent preparation: equilibrate the kit at room temperature for half an hour.
[0099] (2) Add standard: add 50 μL standard.
[0100] (3) Add sample: add 50 μL of sample to be tested to the corresponding well.
[0101] (4) Enzyme incubation: 100 μL of antibody was added to the standard and sample wells, respectively. After sealing the wells, incubate at 37°C for 1 hour.
[0102] (5) Wash the plate: After removing the sealing film, pour out the liquid. Add the washing solution to each well plate, stand for 1 minute each time, then shake out the washing solution and pat dry. Repeat 5 times.
[0103] (6) Color development: Add 50 μL of A and B substrates to each well plate, respectively. Shake well and incubate at 37°C for 15 min.
[0104] (7) Termination: Add 50 μL of termination solution to each well plate to terminate the reaction, and measure the OD value at 450 nm.
[0105] Step 6, data analysis was performed using SPSS 26.0 software. Normally distributed measurement data was presented as mean ± standard deviation , if the variances were homogeneous, One-way ANOVA was used to test the differences between groups, and LSD method was used for multiple comparisons, if the variances were not homogeneous, corrected Welch ANOVA was used to test the differences between groups, and Games-Howell method was used for multiple comparisons. Non-normally distributed measurement data was presented as median (interquartile range) M (IQR), Kruskal-Wallis H test was used, P<0.05 was considered statistically significant.
[0106] Experimental results A) General observation: The mice in the blank group were in good mental state, normal activity, shiny and smooth fur, normal diet and water; the mice in the model group, simple microneedle group, and simple gel paste group were in poor mental state, reduced activity, oily fur, partial hair loss, slightly poor diet, and normal water intake; the mice in the gel paste microneedle combination group were in good mental state, slightly oily hair, partial hair loss, normal diet and water intake.
[0107] B) Comparison of inflammatory factors: As shown in the following table: Compared with the blank group, the IL-6, IL-8, and TNF-α levels of the mice in the model group increased (P<0.001).
[0108] Compared with the model group, the IL-6, IL-8 and TNF-α levels of the microneedle group decreased (P<0.05 / P<0.001 / P<0.001), the IL-6, IL-8 and TNF-α levels of the gel group decreased (P<0.05 / P<0.001 / P<0.001), and the IL-6, IL-8 and TNF-α levels of the gel-microneedle combination group decreased (P<0.01 / P<0.001 / P<0.001).
[0109] Compared with the microneedle group, the IL-6 and IL-8 levels of the gel-microneedle combination group had no statistical difference (P>0.05), and the TNF-α level decreased (P<0.05).
[0110] Compared with the gel group, the IL-6 and TNF-α levels of the gel-microneedle combination group had no statistical difference (P>0.05), and the IL-8 level decreased (P<0.01).
[0111] Note: compared with the blank group, *** P <0.001; compared with the model group, △△△ P <0.001, △△ P <0.01, △ P <0.05; compared with the microneedle group, # P <0.05; compared with the gel group, + P <0.05.
[0112] C) Summary: The ApoE - / - mice established by high-fat diet had significant inflammatory response. The TSA-DMN, TSA gel and TSA-DMN-gel had inhibitory effect on the serum IL-6, IL-8 and TNF-α levels of the ApoE - / - mice. Among them, the inhibitory effect of TSA-DMN-gel on the TNF-α level was better than that of TSA-DMN, and the inhibitory effect on the IL-6 and IL-8 levels was comparable to that of TSA-DMN. The inhibitory effect of TSA-DMN-gel on the IL-8 level was better than that of TSA gel, and the inhibitory effect on the IL-6 and TNF-α levels was comparable to that of TSA gel.
[0113] Experimental Example 1-5: Transdermal penetration experiment: The Franz diffusion cell was used to perform in vitro transdermal penetration experiments on isolated rat skin. The receiving liquid ethanol / PEG-400 / normal saline (volume ratio 5:2:3) was injected into the transdermal diffusion instrument (receiving chamber volume 7 mL). The gel ointment microneedle combination group (containing about 841.31 µg / tablet) and the simple microneedle group (containing about 57.64 µg / tablet) were set to a certain force and placed on the isolated rat skin for 2 min, and the air-permeable medical tape was used to fix it.
[0114] After the treatment was completed, the skin was placed on the receiving chamber, ensuring that the stratum corneum was facing up and the skin tissue was facing the receiving chamber to ensure that the effective diffusion area of the skin was in contact with the liquid surface of the receiving liquid. The rotation speed was maintained at 300 rpm and the temperature was maintained at (37±5) °C to simulate the blood and tissue fluid circulation under the human skin. 1 mL was sampled at 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 24 h, 48 h and 72 h, and an equal amount of isothermal ethanol / PEG-400 and normal saline (volume ratio 5:2:3) was added to the transdermal receiving liquid. HPLC was used for content determination, and the cumulative penetration amount Q was calculated.
[0115] In the formula: Qn is the cumulative penetration amount per unit area of the drug at the nth sampling point (µg / cm 2 ), Cn is the mass concentration of the drug in the receiving liquid at the nth sampling point (µg / mL), Ci is the mass concentration of the drug in the receiving liquid measured at the ith (i≤n-1) sampling point (µg / mL), Vo is the sampling volume (mL), S is the effective transdermal area of the drug (cm 2 , calculated based on the circular area of the DMNs backing layer, S=πr 2 =0.95 cm 2 , V is the receiving pool volume (mL).
[0116] The in vitro transdermal test was performed as shown in Figure 8 The TSA content of the simple microneedle group was detected at 30 min, indicating that the microneedle tips released the drug within 30 min. The Q2h of the simple microneedle group was 9.35 µg / cm 2 , the Q4h was 18.64 µg / cm 2 , the Q8h was 34.67 µg / cm 2 , the Q24h was 52.18 µg / cm 2 , the Q48h was 53.55 µg / cm 2 , and the Q72h was 54.05 µg / cm 2 ; the Q2h of the gel ointment microneedle combination group was 10.65 µg / cm 2 , the Q4h was 19.67 µg / cm2 Q8h was 36.97 µg / cm 2 Q24h was 63.78 µg / cm 2 Q48h was 76.46 µg / cm 2 Q72h was 84.67 µg / cm 2 It can be seen that the simple microneedle group and the gel ointment microneedle combination group showed good controlled release performance and the ability to prolong the drug release period at different time points, but the simple microneedle group tended to balance after 24 hours, while the gel ointment microneedle combination group still maintained the sustained release performance after 24 hours, which verified the advantages of the combination of TSA gel ointment and TSA microneedle.
[0117] The preparation process of TSA-DMN and TSA gel ointment is designed respectively, and the combination of the two is realized, and the TSA-DMN-gel ointment composite drug delivery system is prepared, which significantly improves the drug loading capacity of TSA-DMN and the transdermal performance of TSA gel ointment, and is confirmed to have an efficient anti-inflammatory effect, and the research will further improve the drug loading capacity of traditional Chinese medicine microneedle preparation and enhance the transdermal absorption of drugs.
Claims
1. A soluble microneedle gel paste composition against atherosclerotic inflammation, characterized by, The application relates to a soluble microneedle gel paste composition, which comprises a microneedle matrix and a gel paste (1), the microneedle matrix comprises needle tip matrixes (2) and backing materials (3), the microneedle matrix is formed by regularly arranging a large number of needle tip matrixes (2) on the backing materials (3), the needle tip matrixes (2) are prepared by mixing chondroitin sulfate, polyvinylpyrrolidone and tanshinone IIA, the backing materials (3) are prepared by polyvinyl alcohol, the backing materials (3) are arranged at the bottom of the needle tip matrixes (2), and the gel paste (1) is prepared by dissolving, stirring and baking hydrophilic gel special polyacrylic acid sodium NP-700, glycerol, alumin(i)um glycerophosphate, tartaric acid, ethylenediaminetetraacetic acid disodium EDTA-2Na, polyvinyl alcohol PVA and tanshinone IIA, and the gel paste (1) is arranged at the bottom of the microneedle matrix.
2. A soluble microneedle gel paste composition to combat atherosclerotic inflammation as claimed in claim 1, wherein: The mass ratio of chondroitin sulfate to polyvinylpyrrolidone in the needle tip matrix (2) is 1:1, and 0.8g-1.2g is selected, the tanshinone IIA of the needle tip matrix (2) can be selected from the concentration options of 3mg / ml, 9mg / ml, 12mg / ml, 15mg / ml, 18mg / ml and 21mg / ml, the percentage of the specific components of the gel paste (1) is as follows: NP-700: 5.0%, glycerol: 40%, alumin(i)um glycerophosphate: 0.3%, tartaric acid: 0.2%, ethylenediaminetetraacetic acid disodium EDTA-2Na: 0.05%, polyvinyl alcohol PVA: 0.5%, and the input amount of tanshinone IIA in the gel paste (1) can be 1mg, 3mg, 5mg and 7mg respectively.
3. A soluble microneedle gel paste composition to combat atherosclerotic inflammation as claimed in claim 1 or 2, wherein: The tanshinone IIA content of the soluble microneedle gel paste composition is 841.31+ / -7.34ug.
4. A soluble microneedle gel paste composition to combat atherosclerotic inflammation as claimed in claim 3, wherein: The back surface of the backing material (3) has a circle of side walls (4) which are perpendicular to the backing material (3), the side walls (4) and the back surface of the backing material (3) form a concave surface (5), and the gel paste (1) is filled in the concave surface.
5. A soluble microneedle ointment composition to combat atherosclerotic inflammation as claimed in claim 3, wherein: The back surface of the backing material (3) is respectively provided with a small concave surface (6) at the position corresponding to the needle tip matrix (2), and the gel paste (1) also fills the small concave surface (6).
6. A method for preparing a soluble microneedle gel composition for combating atherosclerotic inflammation as described in any one of claims 1-4, characterized in that, The application further discloses a preparation method of the soluble microneedle gel paste composition, which comprises the following steps: Step 1, preparing a needle tip matrix, selecting chondroitin sulfate CS and polyvinylpyrrolidone PVP-K30 as the needle tip matrix material, taking a certain amount of chondroitin sulfate and polyvinylpyrrolidone, adding 1 times of ethanol aqueous solution (w / w) to stir uniformly, adding different gradient doses of tanshinone IIA, placing in a 4 DEG C refrigerator overnight until swelling completely, pouring the microneedle mold groove surface, centrifuging at 4000 r / min for 10 minutes to make the solution fully fill in the micropores, scraping off the excess matrix solution outside the needle tip with a medicine spoon, and drying in a desiccator at room temperature for 30 minutes to obtain the needle tip matrix / needle tip drug loading layer; Step 3, preparation of soluble microneedle, 15% polyvinyl alcohol PVA backing matrix solution in step 2 is added to the microneedle mold in step 1 for secondary centrifugation, and the air bubbles in the matrix solution are removed under the same conditions, and the soluble microneedle matrix is obtained after drying in the desiccator at room temperature for 24 hours; Step 4, first, add sodium polyacrylate NP-700 special for hydrophilic gel to a beaker containing glycerol, and mix at a speed of 200 rpm as phase A; take tartaric acid and disodium EDTA-2Na as phase B, and add different gradient doses of tanshinone IIA to phase B, and mix with appropriate amount of ethanol solution; Add polyvinyl alcohol PVA to the ethanol solution, and place overnight to swell to remove the generated air bubbles as phase C; add aluminoglycinate to appropriate amount of glycerol, and stir until completely dissolved to obtain phase D; Step 5, under the stirring speed of 200 rpm, add phases B and C to phase A respectively, then add phase D and stir to form a semi-viscous solid fluid, and after ultrasonic treatment for 30 minutes, coat it on the non-woven fabric, and place it in an oven at 50℃ for 24 hours to prepare the gel paste; Step 6, fill appropriate amount of gel paste into the back of the soluble microneedle matrix obtained in step 3.
7. The method for preparing a soluble microneedle gel composition for combating atherosclerotic inflammation as described in claim 6, characterized in that: The last soluble microneedle matrix in step 3 is still in the microneedle mold, and in step 6, appropriate amount of gel paste is filled into the microneedle mold, and the gel paste fills the concave surface on the back of the soluble microneedle matrix.
8. The method for preparing a soluble microneedle gel composition for combating atherosclerotic inflammation as described in claim 6, characterized in that: The last soluble microneedle matrix in step 3 is demolded, and in step 6, appropriate amount of gel paste is filled into the concave surface on the back of the soluble microneedle matrix.
9. A method for preparing a soluble microneedle gel composition for combating atherosclerotic inflammation as described in claim 7 or 8, characterized in that: In step 1, 1g of chondroitin sulfate and 1g of polyvinylpyrrolidone are respectively added to 2ml of ethanol solution (w / w) and stirred uniformly, the concentration of the ethanol solution is 50%-70%, and the different gradient doses of tanshinone IIA are 3mg / ml, 9mg / ml, 12mg / ml, 15mg / ml, 18mg / ml and 21mg / ml, then 2ml of ethanol solution is used, and the amount of 6mg, 24mg, 30mg, 36mg and 42mg is used.
10. The method for preparing a soluble microneedle gel composition for combating atherosclerotic inflammation as described in claim 9, characterized in that: In step 4, the different gradient doses of tanshinone IIA can be selected as 1mg, 3mg, 5mg and 7mg.
